真实世界研究验证，瑞波西利一线治疗 HR+/HER2- 晚期乳腺癌生存优势

文章预览

本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面 ✩ 本文仅供医疗卫生等专业人士参考 审批码：KIS0026639-63377，有效期至2025-06-18，资料过期，视同作废 内容审核：唐颖 项目审核：于轩 参考文献 [1]Howlader, Nadia et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Journal of the National Cancer Institute vol. 106,5 dju055. 28 Apr. 2014. [2]https://seer.cancer.gov/statfacts/html/breast-subtypes.html [3]What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine?: Real-world data from the RIBANNA study (6th interim analysis (IA)).2024 ESMO 216P. [4]Hortobagyi, G N et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast ca ………………………………